AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Arch Biopartners Inc.

$0.65 -$0.25 (-27.61%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0.62
Day Range
$0.65$0.68
Year Range
$0.29$1.21
Market Cap
44.16M
AVG Volume
24.57K
Trailing/Forward PE
-21.65/-
PEG ratio
0.29
Dividend Yield
-
Next Earnings Date
2027-02-02
Primary Exchange
Other OTCUS
Revenue (CAD)
01M2M3M4M2016201720182019202020212022202320242025
ACHFF Revenue (CAD) by year
PeriodRevenue (CAD)
2025275.94K
20242.12M
20231.98M
2022963.9K
20213.89M
202067.89K
201993.88K
20180
20170
20160
Net Income (CAD)
-6M-4M-2M02016201720182019202020212022202320242025
ACHFF Net Income (CAD) by year
PeriodNet Income (CAD)
2025-1.55M
2024-3.92M
2023-3.33M
2022-1.37M
2021-1.17M
2020-4.63M
2019-2.36M
2018-3.2M
2017-1.92M
2016-1.01M
Operating Income (CAD)
-6M-4M-2M02016201720182019202020212022202320242025
ACHFF Operating Income (CAD) by year
PeriodOperating Income (CAD)
2025-1.5M
2024-3.95M
2023-3.35M
2022-2.68M
2021-3.66M
2020-4.64M
2019-2.36M
2018-3.23M
2017-1.91M
2016-1M
EBITDA (CAD)
-4M-2M02M2016201720182019202020212022202320242025
ACHFF EBITDA (CAD) by year
PeriodEBITDA (CAD)
2025-534.21K
2024-3.53M
2023450.81K
2022-59.61K
20211.65M
2020-73.22K
2019-2.25M
2018-3.12M
2017-1.89M
2016-971.83K
Cash Flows (CAD)
-3M-2M-1M01M2016201720182019202020212022202320242025
ACHFF Cash Flows (CAD) by year
PeriodCash Flows (CAD)
2025-1.62M
2024-2.35M
2023-234.07K
2022479.48K
2021-2.98M
2020-1.9M
2019-1.77M
2018-2.16M
2017-760.17K
2016-730.53K
EPS (CAD)
-0.08-0.06-0.04-0.0202016201720182019202020212022202320242025
ACHFF EPS (CAD) by year
PeriodEPS (CAD)
2025-0.02
2024-0.06
2023-0.05
2022-0.02
2021-0.02
2020-0.08
2019-0.04
2018-0.06
2017-0.04
2016-0.02
Expenses (CAD)
-2M02M4M6MR&DSG&A2016201720182019202020212022202320242025
ACHFF Expenses (CAD) by year
PeriodExpenses (CAD)
20251.14M
20245.45M
20234.67M
20221.73M
20214.42M
20204.26M
20192.06M
20182.87M
20171.72M
2016776.76K
Cash & Debt (CAD)
02M4M6MCashLong Term DebtShort Term Debt2016201720182019202020212022202320242025
ACHFF Cash & Debt (CAD) by year
PeriodCash & Debt (CAD)
20252.1K
20242.97K
2023831.27K
2022506.35K
2021448.24K
2020653.68K
2019400.37K
2018544.32K
201742.58K
2016199.85K
Debt ratios
-6-4-202420182019202020212022202320242025
ACHFF Debt ratios by year
PeriodDebt ratios
2025-0.77
2024-1.86
20232.13
2022-5.36
2021-1.24
2020-0.37
2019-0.3
2018-0.14
Margins
-4000%-3000%-2000%-1000%0%20152019202020212022202320242025
ACHFF Margins by year
PeriodMargins
2025-25.62%
2024-78.02%
2023-191.21%
2022-129.02%
2021-3.1%
2020-3423.61%
2019-1655.35%
2015-982.28%
Return on Capital
0%100%200%300%400%2016201720182019202020212022202320242025
ACHFF Return on Capital by year
PeriodReturn on Capital
202539.99%
202490.19%
202360.38%
202230.56%
202130.04%
2020119.65%
201981.25%
2018305.78%
2017340.12%
2016391.8%
Shares Outstanding
020M40M60M80M2016201720182019202020212022202320242025
ACHFF Shares Outstanding by year
PeriodShares Outstanding
202566.11M
202460.77M
202362.6M
202262.33M
202161.96M
202059.92M
201958.65M
201857.03M
201755.09M
201653.37M
Book Value Per Share (CAD)
-0.1-0.08-0.05-0.03-02016201720182019202020212022202320242025
ACHFF Book Value Per Share (CAD) by year
PeriodBook Value Per Share (CAD)
2025-0.06
2024-0.07
2023-0.09
2022-0.07
2021-0.06
2020-0.06
2019-0.05
2018-0.02
2017-0.01
2016-0
Total Assets (CAD)
01M2M3M2016201720182019202020212022202320242025
ACHFF Total Assets (CAD) by year
PeriodTotal Assets (CAD)
2025104.53K
2024935.62K
20231.17M
2022621.64K
20212.67M
2020741.3K
2019567.98K
2018672.69K
201767.94K
2016227.03K
PE Ratio
2004006008001000med 404.96Apr 22May 22Jun 22Jul 22Jul 22Aug 22Sep 22
ACHFF PE Ratio by year
PeriodPE Ratio
Sep 22212.84
Sep 22226.6
Sep 22227.98
Sep 22228.68
Aug 22243.19
Aug 22239.42
Aug 22248.08
Aug 22244.81
Jul 22250.3
Jul 22248.07
Jul 22250.22
Jul 22259.51
Jul 22213.68
Jun 22550.41
Jun 22576.85
Jun 22598.81
Jun 22591.46
May 22608.33
May 22627.35
May 22716.79
May 22780.21
Apr 22787.38
Apr 22802.53
Apr 22814.05
Apr 22817.49
Apr 22833.43
Free Cash Flow Yield
-6%-4%-2%0%med -2.38%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ACHFF Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-1.79%
Sep 26-1.58%
Aug 26-1.55%
Aug 26-1.48%
Aug 26-1.41%
Aug 26-1.58%
Jul 26-2.01%
Jul 26-1.9%
Jul 26-1.91%
Jul 26-1.91%
Jul 26-1.88%
Jun 26-2.6%
Jun 26-3.49%
Jun 26-4.81%
Jun 26-4.84%
May 26-5.42%
May 26-5.37%
May 26-5.57%
May 26-5.41%
May 26-5.42%
Apr 26-5.05%
Apr 26-5.19%
Apr 26-4.3%
Apr 26-4.21%
Mar 26-4.53%
Mar 26-4.43%
Mar 26-3.59%
Mar 26-3.14%
Feb 26-3.09%
Feb 26-2.7%
Feb 26-2.64%
Feb 26-3.06%
Jan 26-2.36%
Jan 26-1.97%
Jan 26-1.78%
Jan 26-1.85%
Jan 26-1.99%
Dec 25-2.25%
Dec 25-2.27%
Dec 25-2.2%
Dec 25-2.17%
Nov 25-2.67%
Nov 25-2.7%
Nov 25-2.65%
Nov 25-2.65%
Oct 25-2.8%
Oct 25-2.85%
Oct 25-2.89%
Oct 25-2.52%
Oct 25-2.3%
Sep 25-3.11%
Sep 25-2.62%
Sep 25-2.63%
Sep 25-2.72%
Aug 25-2.6%
Aug 25-2.61%
Aug 25-2.59%
Aug 25-2.54%
Aug 25-2.51%
Jul 25-2.66%
Jul 25-2.5%
Jul 25-2.51%
Jul 25-2.45%
Jun 25-2.24%
Jun 25-2.41%
Jun 25-2.24%
Jun 25-2.25%
May 25-2.35%
May 25-2.39%
May 25-2.44%
May 25-2.41%
May 25-2.39%
Apr 25-2.38%
Apr 25-2.37%
Apr 25-2.22%
Apr 25-2.46%
Mar 25-2.25%
Mar 25-2.1%
Mar 25-2.07%
Mar 25-2.2%
Feb 25-2.12%
Feb 25-2.01%
Feb 25-2.06%
Feb 25-2.05%
Jan 25-2.11%
Jan 25-2.01%
Jan 25-2.04%
Jan 25-2%
Jan 25-1.94%
Dec 24-2.38%
Dec 24-2.5%
Dec 24-2.32%
Dec 24-2.23%
Nov 24-2.22%
Nov 24-2.26%
Nov 24-2.16%
Nov 24-2.16%
Nov 24-2.26%
Oct 24-2.16%
Oct 24-2.09%
Price to Sales
-1000-5000500med 62.21Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ACHFF Price to Sales by year
PeriodPrice to Sales
Sep 26381.76
Sep 26433.42
Aug 26441.49
Aug 26463.86
Aug 26484.49
Aug 26432.84
Jul 26339.98
Jul 26360.96
Jul 26358.18
Jul 26358.56
Jul 26365.09
Jun 26381.08
Jun 26284.53
Jun 26206.25
Jun 26204.93
May 26182.85
May 26184.87
May 26178.18
May 26183.33
May 26182.93
Apr 26196.61
Apr 26191.02
Apr 26230.73
Apr 26235.83
Mar 26129.77
Mar 26132.75
Mar 26163.52
Mar 26187.26
Feb 26190.18
Feb 26217.94
Feb 26222.91
Feb 26191.9
Jan 26249.53
Jan 26298.98
Jan 26330.11
Jan 26318.24
Jan 26295.27
Dec 25-956.25
Dec 25-950.43
Dec 25-980.93
Dec 25-994.2
Nov 25-808.65
Nov 25-799.9
Nov 25-812.66
Nov 25-812.13
Oct 25-770.56
Oct 25-755.74
Oct 25-746.25
Oct 25-853.9
Oct 25-939.39
Sep 25-373.59
Sep 25-442.95
Sep 25-441.56
Sep 25-426.1
Aug 25-445.55
Aug 25-444.52
Aug 25-448.02
Aug 25-457.14
Aug 25-461.93
Jul 25-436.89
Jul 25-463.3
Jul 25-462.16
Jul 25-473.26
Jun 2562.21
Jun 2557.87
Jun 2562.21
Jun 2561.8
May 2559.26
May 2558.31
May 2556.98
May 2557.77
May 2558.2
Apr 2558.35
Apr 2558.75
Apr 2562.59
Apr 2556.62
Mar 2549.18
Mar 2552.6
Mar 2553.49
Mar 2550.18
Feb 2552.17
Feb 2554.95
Feb 2553.6
Feb 2554
Jan 2552.4
Jan 2555.03
Jan 2554.31
Jan 2555.32
Jan 2557.08
Dec 2482.98
Dec 2478.84
Dec 2485.16
Dec 2488.54
Nov 2488.87
Nov 2487.42
Nov 2491.32
Nov 2491.41
Nov 2487.25
Oct 2491.31
Oct 2494.47
EV/EBITDA
050010001500med 205.66Nov 21Feb 22Jun 22Sep 22Dec 22Dec 23Mar 24
ACHFF EV/EBITDA by year
PeriodEV/EBITDA
Mar 24319.5
Mar 24349.3
Mar 24310.04
Mar 24250.79
Mar 24218.22
Feb 24219.35
Feb 24203.97
Feb 24207.36
Feb 24201.85
Jan 24225.84
Jan 24218.03
Jan 24215.87
Jan 24211.42
Dec 23215.24
Dec 231249.84
Dec 231226.91
Dec 231211.14
Dec 231259.22
Nov 23955.52
Nov 23968.58
Nov 23882.71
Nov 23864.36
Oct 23910.35
Oct 23940.37
Oct 23964.57
Oct 23936.6
Sep 23953.84
Dec 22244.21
Dec 22257.47
Dec 22258.84
Dec 22259.55
Nov 22258.93
Nov 22267.33
Nov 22279.58
Nov 22286.93
Oct 22288.33
Oct 22289.17
Oct 22267.42
Oct 22264.5
Sep 22269.92
Sep 22112.22
Sep 22119.33
Sep 22120.04
Sep 22120.4
Aug 22127.91
Aug 22125.96
Aug 22130.44
Aug 22128.75
Jul 22131.59
Jul 22130.44
Jul 22131.55
Jul 22136.35
Jul 22112.65
Jun 22105.7
Jun 22110.67
Jun 22114.79
Jun 22113.41
May 22116.58
May 22120.16
May 22136.97
May 22148.9
Apr 22150.24
Apr 22153.09
Apr 22155.26
Apr 22155.9
Apr 22158.9
Mar 22148.03
Mar 22138.17
Mar 22128.72
Mar 22125.63
Feb 22125.86
Feb 22137.8
Feb 22141.96
Feb 22139.9
Jan 22126.5
Jan 22136.34
Jan 22138.09
Jan 22140.5
Dec 21133.35
Dec 21264.76
Dec 21275.62
Dec 21291.76
Dec 21338.82
Nov 21323.53
Nov 21289.83
Nov 21254.65
Nov 21226.22
Oct 21201.08
Oct 21184.73
Oct 21171.86
Oct 21149.11
Oct 21126.15
Price/Operating Cashflow
0100200300400med 162.24Jan 23Feb 23Mar 23Sep 23Oct 23Nov 23Dec 23
ACHFF Price/Operating Cashflow by year
PeriodPrice/Operating Cashflow
Dec 2352.01
Dec 2351.02
Dec 2350.34
Dec 2352.42
Nov 2339.28
Nov 2339.85
Nov 2336.13
Nov 2335.34
Oct 2337.33
Oct 2338.63
Oct 2339.67
Oct 2338.46
Sep 2339.21
Mar 23282.2
Mar 23272.05
Mar 23303.67
Mar 23333.06
Feb 23275.93
Feb 23322.23
Feb 23346.89
Feb 23348.41
Jan 23350.8
Jan 23372.1
Jan 23393.46
Jan 23356.49
Dec 22366.15
Arch Biopartners Inc.
ACHFF
Stockpicker

Video analysis: ACHFF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ACHFF

Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide

globenewswire.com · 31 Aug 2026

Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide

TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related study documents for the Company's ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”).

Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program

globenewswire.com · 17 Jul 2026

Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program

TORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company's pre-IND IL-32 chronic kidney disease (“CKD”) program.

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

globenewswire.com · 8 Jul 2026

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.